doses currently produced globally every year1
more iodinated contrast media doses to be delivered annually by 20251
accredited contrast media production facilities globally
invested over the last decade to increase capacity2
GE HealthCare has a distinguished heritage of contrast media development, offering a comprehensive product range across modalities, with a range of concentrations and innovative packaging choices.
Active Pharmaceutical Ingredients investment
$80 million invested to expand production at our Lindesnes, Norway API facility.
Contrast media production investment
Opening of new €30m manufacturing line in Cork to increase contrast media supply.
1. GE HealthCare Data on File: Planned Investment 2022
2. GE HealthCare Data on File: Contrast Media Demand; 2022
3. Dhaliwal et al. Int J Life Cycle Assess 2014; 19: 1965-73.
4. GE HealthCare Data on File: iodine-recycling program 2022
cGMP: Current Good Manufacturing Practice
